相似文献
1
Visualized Efficacy of Andexanet Alfa in an Elderly Trauma Patient with an Unstable Pelvic Fracture.
JMA J. 2024 Jul 16;7(3):438-440. doi: 10.31662/jmaj.2024-0007. Epub 2024 Jun 3.
2
Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey.
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241238013. doi: 10.1177/10760296241238013.
3
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
Clin Neurol Neurosurg. 2020 Aug;195:106070. doi: 10.1016/j.clineuro.2020.106070. Epub 2020 Jul 4.
4
Transient or extended reversal of apixaban anticoagulation by andexanet alfa is equally effective in a porcine polytrauma model.
Br J Anaesth. 2019 Aug;123(2):186-195. doi: 10.1016/j.bja.2019.04.059. Epub 2019 Jun 13.
5
Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries.
Emerg Med J. 2024 Feb 20;41(3):162-167. doi: 10.1136/emermed-2023-213229.
6
Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study.
West J Emerg Med. 2023 Sep;24(5):939-949. doi: 10.5811/westjem.60587.
7
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Crit Care. 2022 Jun 16;26(1):180. doi: 10.1186/s13054-022-04043-8.
8
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
J Thromb Thrombolysis. 2022 Jan;53(1):167-175. doi: 10.1007/s11239-021-02495-3. Epub 2021 Jun 8.
9
Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
J Thromb Thrombolysis. 2023 Jan;55(1):149-155. doi: 10.1007/s11239-022-02715-4. Epub 2022 Nov 10.
10
Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.
Int J Stroke. 2024 Jun;19(5):506-514. doi: 10.1177/17474930241230209. Epub 2024 Mar 8.
本文引用的文献
1
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
J Atheroscler Thromb. 2024 Mar 1;31(3):201-213. doi: 10.5551/jat.64223. Epub 2023 Aug 26.
2
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Circulation. 2023 Mar 28;147(13):1026-1038. doi: 10.1161/CIRCULATIONAHA.121.057844. Epub 2023 Feb 20.
3
Andexanet Alfa (Andexxa) for the Reversal of Direct Oral Anticoagulants.
P T. 2019 Sep;44(9):530-549.
Zotero 插件
